Current label evidence
Vyleesi reports a 1% focal-hyperpigmentation warning, not a rate for every dark spot
The current Vyleesi prescribing information, published on DailyMed in November 2025, reports focal hyperpigmentation in 1% of patients who received the studied labeled-use pattern. Reported areas included the face, gingiva, and breasts. The label says risk was higher in people with darker skin and with daily dosing, that resolution was not confirmed in some patients, and that discontinuation should be considered if hyperpigmentation develops. These are product-specific trial and labeling findings; they do not diagnose one person’s skin change or predict whether it will resolve.
- The 1% figure describes focal hyperpigmentation reported with FDA-approved Vyleesi; it is not a rate for all skin-color changes, all bremelanotide products, or every population.
- Higher observed risk in darker skin does not mean a change is expected or harmless, and it should not be used to dismiss a patient’s concern or delay examination.
- The label does not provide a reliable onset, shade, size, distribution, or time-to-resolution rule that can be used as an online countdown.
What to document
Skin, gum, breast, and injection-site changes should be described separately
“Darkening” can refer to a new focal spot, diffuse color change, gum or oral pigmentation, a mark at an injection site, bruising, irritation after a topical product, or a pre-existing lesion that has changed. Those findings can have different causes and urgency. A clinician may need the location, border, color, size, texture, symptoms, timing, photographs, treatment history, and examination rather than a single description such as “PT-141 tan.”
- Use dated photographs in similar lighting and include a size reference when practical; do not rely on filters, edited images, or seller before-and-after examples.
- Report itching, pain, tenderness, swelling, bleeding, crusting, ulceration, drainage, color variation, rapid growth, mouth sores, eye symptoms, fever, or feeling acutely unwell.
- Share recent sun exposure, tanning products, skin procedures, dental work, hormone or pregnancy context, new medicines, supplements, cosmetics, irritation, injury, and prior pigment or skin conditions.
Product and route identity
Vyleesi evidence cannot establish risk for compounded or research-use PT-141
Vyleesi is an FDA-approved bremelanotide subcutaneous product for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Peptide12 separately lists a clinician-reviewed compounded PT-141 injection pathway. A patient-specific compounded preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, container, labeling, storage, and pharmacy controls. Nasal sprays, troches, loose vials, blends, and research-use products should not inherit Vyleesi’s 1% rate or quality assumptions.
- Confirm the active ingredient, route, manufacturer or dispensing pharmacy, concentration, patient label, prescriber, refill or lot, storage history, and any product or formulation change.
- Do not assume a non-injection route prevents pigmentation, and do not switch routes or products to manage a skin change without clinician review.
- Avoid research-use products, no-prescription checkout, copied reconstitution or dose instructions, hidden pharmacy sourcing, guaranteed pigment prevention, and sellers that call every color change normal.
What not to improvise
Do not self-treat pigmentation before the change is assessed
Bleaching agents, acids, retinoids, hydroquinone products, peels, lasers, supplements, and home remedies can irritate skin, obscure the original finding, interact with other care, or delay diagnosis. The Vyleesi label says discontinuation should be considered if hyperpigmentation develops, but that is a clinician decision—not permission to stop, repeat, restart, or change a prescription from a generic article. A skin or dental professional may be needed when the location or appearance cannot be evaluated safely through telehealth.
- Do not scrub, peel, lance, cover with a tattoo, or apply a prescription-strength product to a new lesion or oral change based on forum advice.
- Do not use extra medication, a different route, a seller-provided “microdose,” or a supplement stack in an attempt to prevent or reverse pigmentation.
- Ask who should examine the area, whether treatment should pause pending review, and how photographs, pharmacy details, and an adverse-event report should be handled.
Escalation
Persistent pigmentation needs follow-up; rapidly changing or injured tissue needs prompt assessment
Focal pigmentation itself is not automatically an emergency, but the cause cannot be confirmed from a search result. Contact the prescriber promptly for a new change during treatment, especially when it persists, expands, recurs, follows a refill or formulation change, involves the mouth or breast, or causes distress. Rapid growth, bleeding, ulceration, severe pain, marked swelling, eye involvement, significant mouth injury, widespread rash, breathing trouble, fainting, fever, or feeling acutely ill should bypass routine seller or portal messaging for in-person care.
- Seek emergency care for breathing difficulty, throat tightness, facial or tongue swelling, fainting, severe confusion, or rapidly developing whole-body allergy symptoms.
- Seek prompt local assessment for rapid pigment or lesion change, bleeding, ulceration, severe pain, drainage, marked swelling, eye involvement, fever, or significant mouth symptoms.
- Arrange prescriber follow-up before another treatment decision for new, persistent, expanding, recurrent, or treatment-limiting pigmentation even when there are no emergency symptoms.